美国 · SEC FORM 4
CRESCENT BIOPHARMA, INC.
CBIO · Nasdaq · CIK 0001253689 · Healthcare · Biotechnology
内部人信号
60.9 / 100
1 位买方 · 1 条买入交易行 · $12.4M 买入总额
为什么有这个信号？
买方广度较低
买入规模较强
角色较强
近期性较低
确信度较强
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
Cluster+7.0 / 35
买入规模+23.1 / 25
角色+20.0 / 20
近期性+2.1 / 10
确信度+8.8 / 10
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是：Director,TenPercentOwner
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
McNeill JonathanPresident and COO
▼▼▼
Brumm Joshua TChief Executive Officer
▼▼▼
Scalzo Richard WilliamChief Financial Officer
▼▼
Pinkas JanChief Scientific Officer
▼▼
Lynch RyanSee Remarks
▼▼
Im Ellie EunkyungChief Medical Officer
▼▼
● 买入▼ 卖出○ 其他
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
合资格买方1
买入集中度100%最大买方： Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas · $12.4M
聚集买入 · 15天1 insider峰值活动： 2026-07-16–2026-07-16
Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
60.9 / 100
最新留档分数
↓ -0.1 pts相对上一个留档快照
- 61.0
- 60.9
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
2买入
16卖出
16其他 Form 4 交易行
24SEC 申报 · 365天
买入1 qualifying P line(s) · 180 days
卖出16 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,777,172
- 上期报告
- 3,407,158
- 日均成交量
- 697,402
- 回补天数
- 6.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-16 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | 买入 (P) | Ordinary Shares | 853,450 | USD 14.50 | USD 12,375,025 | SEC 申报 ↗ |
| 2025-12-04 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | 买入 (P) | Ordinary Shares | 1,360,000 | USD 13.41 | USD 18,237,600 | SEC 申报 ↗ |
| 2024-06-21 | Rock Edwin | 买入 (P) | Common Stock | 115,000 | USD 0.27 | USD 31,050 | SEC 申报 ↗ |
| 2024-06-20 | Rock Edwin | 买入 (P) | Common Stock | 190,000 | USD 0.25 | USD 47,500 | SEC 申报 ↗ |
| 2024-06-18 | Hahn Brian M. | 买入 (P) | Common Stock | 17,500 | USD 0.25 | USD 4,375 | SEC 申报 ↗ |
| 2023-09-22 | Rock Edwin | 买入 (P) | Common Stock | 30,403 | USD 1.38 | USD 41,956 | SEC 申报 ↗ |
| 2023-09-21 | Rock Edwin | 买入 (P) | Common Stock | 35,000 | USD 1.38 | USD 48,300 | SEC 申报 ↗ |
| 2023-05-10 | JUNIUS DANIEL M | 买入 (P) | Common Stock | 30,000 | USD 1.56 | USD 46,800 | SEC 申报 ↗ |
| 2023-05-08 | Johnson Bruce S | 买入 (P) | Common Stock | 13,500 | USD 1.57 | USD 21,195 | SEC 申报 ↗ |
| 2023-02-24 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 100,000 | USD 1.70 | USD 170,000 | SEC 申报 ↗ |
| 2023-02-23 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 200,000 | USD 1.75 | USD 350,000 | SEC 申报 ↗ |
| 2023-02-22 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 150,000 | USD 1.79 | USD 268,500 | SEC 申报 ↗ |
| 2023-02-21 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 50,000 | USD 1.85 | USD 92,500 | SEC 申报 ↗ |
| 2023-02-17 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 200,000 | USD 1.71 | USD 342,000 | SEC 申报 ↗ |
| 2023-02-16 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 315,266 | USD 1.68 | USD 529,647 | SEC 申报 ↗ |
Form 4 申报证据
34 transaction lines in the latest 365-day window; 122 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | McNeill Jonathan | 卖出 (S) | Ordinary Shares | 3,839 | USD 16.71 | USD 64,150 | SEC 申报 ↗ |
| 2026-09-18 | Brumm Joshua T | 卖出 (S) | Ordinary Shares | 7,837 | USD 16.71 | USD 130,956 | SEC 申报 ↗ |
| 2026-09-16 | Scalzo Richard William | 卖出 (S) | Ordinary Shares | 568 | USD 17.90 | USD 10,167 | SEC 申报 ↗ |
展开近期 Form 4 证据 (26 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | McNeill Jonathan | 卖出 (S) | Ordinary Shares | 3,839 | USD 16.71 | USD 64,150 | SEC 申报 ↗ |
| 2026-09-18 | Brumm Joshua T | 卖出 (S) | Ordinary Shares | 7,837 | USD 16.71 | USD 130,956 | SEC 申报 ↗ |
| 2026-09-16 | Scalzo Richard William | 卖出 (S) | Ordinary Shares | 568 | USD 17.90 | USD 10,167 | SEC 申报 ↗ |
| 2026-09-16 | Pinkas Jan | 卖出 (S) | Ordinary Shares | 658 | USD 17.90 | USD 11,778 | SEC 申报 ↗ |
| 2026-09-16 | McNeill Jonathan | 卖出 (S) | Ordinary Shares | 731 | USD 17.90 | USD 13,085 | SEC 申报 ↗ |
| 2026-09-16 | Lynch Ryan | 卖出 (S) | Ordinary Shares | 240 | USD 17.90 | USD 4,296 | SEC 申报 ↗ |
| 2026-09-16 | Im Ellie Eunkyung | 卖出 (S) | Ordinary Shares | 623 | USD 17.90 | USD 11,152 | SEC 申报 ↗ |
| 2026-09-16 | Brumm Joshua T | 卖出 (S) | Ordinary Shares | 1,610 | USD 17.90 | USD 28,819 | SEC 申报 ↗ |
| 2026-09-16 | Bispham Barbara Harlin | 卖出 (S) | Ordinary Shares | 620 | USD 17.90 | USD 11,098 | SEC 申报 ↗ |
| 2026-07-16 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | 买入 (P) | Ordinary Shares | 853,450 | USD 14.50 | USD 12,375,025 | SEC 申报 ↗ |
| 2026-06-22 | Scalzo Richard William | 卖出 (S) | Ordinary Shares | 1,112 | USD 17.99 | USD 20,005 | SEC 申报 ↗ |
| 2026-06-22 | Pinkas Jan | 卖出 (S) | Ordinary Shares | 1,288 | USD 17.99 | USD 23,171 | SEC 申报 ↗ |
| 2026-06-22 | McNeill Jonathan | 卖出 (S) | Ordinary Shares | 20,549 | USD 17.99 | USD 369,677 | SEC 申报 ↗ |
| 2026-06-22 | Lynch Ryan | 卖出 (S) | Ordinary Shares | 465 | USD 17.99 | USD 8,365 | SEC 申报 ↗ |
| 2026-06-22 | Im Ellie Eunkyung | 卖出 (S) | Ordinary Shares | 1,219 | USD 17.99 | USD 21,930 | SEC 申报 ↗ |
| 2026-06-22 | Brumm Joshua T | 卖出 (S) | Ordinary Shares | 42,305 | USD 17.99 | USD 761,067 | SEC 申报 ↗ |
| 2026-06-22 | Bispham Barbara Harlin | 卖出 (S) | Ordinary Shares | 1,218 | USD 17.99 | USD 21,912 | SEC 申报 ↗ |
| 2025-12-15 | Scalzo Richard William | 奖励／授予 (A) | Ordinary Shares | 19,422 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | Pinkas Jan | 奖励／授予 (A) | Ordinary Shares | 22,507 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | McNeill Jonathan | 奖励／授予 (A) | Ordinary Shares | 25,507 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | Lynch Ryan | 奖励／授予 (A) | Ordinary Shares | 12,378 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | Im Ellie Eunkyung | 奖励／授予 (A) | Ordinary Shares | 21,298 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | Doughty Christopher Grant | 奖励／授予 (A) | Ordinary Shares | 22,714 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | Brumm Joshua T | 奖励／授予 (A) | Ordinary Shares | 55,117 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-15 | Bispham Barbara Harlin | 奖励／授予 (A) | Ordinary Shares | 18,422 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-04 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | 买入 (P) | Ordinary Shares | 1,360,000 | USD 13.41 | USD 18,237,600 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CBIO |
| CIK | 0001253689 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 122 transaction lines from 2020-01-06 to 2026-09-18 34 P purchase lines · 42 S sale lines · 46 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.